ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2020
COVID-19 and off label use of drugs: an ethical viewpoint.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Pooled it
- Navigating the ethical terrain: Off-label and experimental treatments in medical case reports.World journal of methodology · 2025Article
- A Roadmap for the Application of Convalescent Plasma and Hyperimmune Globulins in Emerging Viral Outbreaks.TheScientificWorldJournal · 2025Review
- Off-Label Pediatric Medication Prescribing and Dispensing: Awareness and Attitudes among Community Pharmacists: A Questionnaire-Based Study.Pharmacy (Basel, Switzerland) · 2024Article
- Current trends in pharmaceutical industry: Post -CoVid-19 pandemic effects.Bioinformation · 2024Article
- Off-label prescription: developing a guideline and validating an instrument to measure physicians' and clinical pharmacists' knowledge and attitudes toward off-label medication use.Journal of diabetes and metabolic disorders · 2023Article
- Erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit cytopathic effect, papain-like protease, and MFrontiers in cellular and infection microbiology · 2023Article
- Off-label use of drugs in pediatrics: a scoping review.European journal of pediatrics · 2022Article
- Ethical review of off-label drugs during the COVID-19 pandemic.World journal of clinical cases · 2022Review
- Drug Prescriptions in the Outpatient Management of COVID-19: Evidence-Based Recommendations Versus Real Practice.Frontiers in pharmacology · 2022Article
- Low Brachial Artery Flow-Mediated Dilation Predicts Worse Prognosis in Hospitalized Patients with COVID-19.Journal of clinical medicine · 2021Article
- Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany-An Ethical Analysis.International journal of environmental research and public health · 2021Article
- The FDA and the COVID-19: A political economy perspective.Southern economic journal · 2021Article
- Vancomycin presoaking of hamstring autografts to prevent infection in anterior cruciate ligament reconstruction: a narrative review.EFORT open reviews · 2021Review
- COVID-19 and the "Stay at home" recommendation: An ethnographic study.Journal of education and health promotion · 2021Article
- Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.The American journal of medicine · 2021Review
- Short and long term impacts of COVID-19 on the pharmaceutical sector.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Article
- The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Observational
- Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).International journal of molecular medicine · 2020Review
- Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 outbreak is rapidly spread over the world and kills infected patients. There is no proven medication for its treatment, so, all of the medications used for treatment are considered to be off-label. Off-label uses are not under regulation in the outbreak because there is no specific regulation for this condition.
objectivesIn this short communication we aim at describing two ways of off-label use as clinical practice or investigational use. Further, we will describe the third way of off-label use, we named it pseudo-research and then we will state the most possible ethical challenges of off-label use for better perceptions and responsibility.
resultsThe WHO considers off-label uses as country-specific. All international regulatory bodies consider off-label prescription as the physician's responsibility and legal by necessitating some requirements. There is no international guideline for regulating investigational off-label uses as clinical practice.
conclusionThere are different types of approaches, none of them is comprehensive and conclusive. Furthermore, respecting the four ethical principles necessitates codification and strict regulation of off-label uses either as clinical practice or investigational. Besides, compilation of a special guideline based on ethical principles especially non-maleficence and autonomy for investigational off-label uses in disasters is highly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.